Chengdu Pilot

Chengdu Pilot Drug Development Co., Ltd. is a biotechnology company specializing in the development of new drugs.

Company Overview

• company identification: Chengdu Pilot Drug Development Co.
• stock code (computing): 688222
• Established: February 22, 2012
• Headquarters location: Chengdu, China
• Launch date: April 16, 2020 (TechCrunch listing)
• Main business: new drug development, technical advice, technology transfer and technical services

Company strength and honor

• Chengdu Pilot is committed to building a world-class innovative biopharmaceutical company with subsidiaries in Cambridge, UK and Houston, USA.
• The company possesses the world's leading DNA-encoded compound library technology (DEL technology) platform, as well as core technology platforms such as molecular fragmentation and 3D structure information-based drug design technology (FBDD/SBDD), oligonucleic acid new drug discovery and development-related technology (STO) and targeted protein degradation-related technology (TPD).
• Chengdu Pilot has been awarded the title of high-tech enterprise and the title of Sichuan Pilot Compound Screening Engineering and Technology Research Center, and has twice been awarded the "CASREGISTRYINNOVATOR" certificate by the Chemical Abstracts Service under the American Chemical Society.

R&D Pipeline & Products

• Chengdu Pilot has established a pipeline of self-developed new drugs, with about 20 in-house new drug projects at different stages of clinical and preclinical stages, of which 4 projects have obtained clinical trial approvals and entered into clinical trials.
• The Company's main products and services include DEL screening services, DEL library customization services, chemical synthesis services, and transfer of new drug discovery projects.
• Chengdu Pioneer's DNA-encoded compound library has more than 1,200 billion small molecule species, which is currently the largest physical small molecule compound library with the largest variety of compound backbones in the world.

Technological innovation and R&D capabilities

• Chengdu Pioneer has always focused on the development, application and upgrading of DNA-encoded compound library (DEL) technology and has taken a leading position in this field.
• The company has excellent design quality and synthesis quality in the field of DEL technology, which can cover most of the structures contained in small molecules and known biologically active molecules that are already drug-ready, with deeper extensions.
• Chengdu Pioneer has accumulated rich experience in sequence design, nucleic acid synthesis and modification, and is capable of directly designing, synthesizing and upgrading and optimizing interfering nucleic acid sequences and antisense nucleic acid sequences for specific genes to meet the requirements of high activity and high selectivity.

Market Placement and M&A Strategy

• Chengdu Pilot is actively seeking to expand at the market level, especially for companies in the domestic market, to provide the company with market supplementation and a direct link to future drug launches.
• In 2022, the Company set up a holding subsidiary, First East Pharmaceuticals, and a participating subsidiary, First Derivative Bio, to deepen its layout in the field of nucleic acid drug development.
• Chengdu Pilot has also set up an M&A fund, "Rongchuang Pilot Fund", aiming to further enhance the company's comprehensive competitiveness through mergers and acquisitions and integration of targets that meet the company's development needs in terms of technological complementation, scale expansion or market expansion.

Corporate Vision and Future Prospects

• Chengdu Pilot's vision is to become a leading global biopharmaceutical company providing innovative medicines and medical services to patients worldwide.
• In the future, the Company will continue to deepen its efforts in the field of small molecule and nucleic acid drug discovery and optimization, continue to promote innovation, and actively utilize its own advantages and resources for the layout of the whole industry chain.
• Chengdu Pioneer will join hands with all parties to promote the high-quality development of the biopharmaceutical industry and make greater contributions to the cause of human health.

To summarize, Chengdu Pilot is a biotechnology company focusing on new drug development with strong technical strength and rich R&D pipeline. In the future, with the continuous progress of technology and market expansion, the company is expected to achieve more significant achievements and breakthroughs in the field of biopharmaceuticals.